Clinical Characterization of Cancer Therapy-induced Adverse Sequelae and Mechanism-based Interventional Strategies (R01 Clinical Trial Optional)
Department of Health and Human Services
The purpose of this Funding Opportunity Announcement (FOA) is to support collaborative research projects designed to address adverse sequelae of cancer therapies that persist and become chronic comorbidities or develop as delayed posttreatment effects. This FOA supports basic, translational, and clinical research projects that seek to identify the mechanisms of therapy-induced adverse sequelae, clinically characterize the adverse sequelae, or translate the mechanistic understanding into therapeutic approaches to prevent or minimize the development of long-term sequelae. Research projects should focus on mechanistic studies with translational endpoints and longitudinal clinical phenotyping to
Funding
Award size
Not specified
Type
Grant
Dates
Deadline
Later
Posted
11/06/2024
Closes
2028-01-07
Eligibility
Eligibility
Special district governmentsPublic and State controlled institutions of higher educationNonprofits having a 501(c)(3) status with the IRS, other than institutions of higher educationNative American tribal governments (Federally recognized)State governmentsNonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher educationPrivate institutions of higher educationFor profit organizations other than small businessesCounty governmentsIndependent school districtsPublic housing authorities/Indian housing authoritiesSmall businessesOthers (see text field entitled "Additional Information on Eligibility" for clarification)City or township governmentsNative American tribal organizations (other than Federally recognized tribal governments)
Program
Funding area
Education - EDHealth - HL
Opportunity #
PAR-25-145
Source
Status
Open
Market
Government
Level
Federal
Source
Grants.gov